LNX3 CRISPR/Cas9 KO Plasmid (h): sc-403866
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LNX3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LNX3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LNX3 CRISPR/Cas9 KO Plasmid (h) | sc-403866 | 20 µg | $397.00 |
Overview
PDZRN3 encodes LNX3, a PDZ domain–containing RING-type E3 ubiquitin ligase implicated in ubiquitin-dependent control of protein stability and trafficking. Through its PDZ-mediated scaffolding interactions and RING-dependent ubiquitination activity, LNX3 is positioned to regulate signaling network architecture at the plasma membrane and within junctional or cytoskeletal compartments, influencing processes such as cell polarity, adhesion dynamics, and differentiation programs. PDZRN3/LNX3 has been connected to pathways involved in developmental patterning and tissue remodeling, where altered ubiquitin signaling can shift transcriptional outputs and cellular state transitions. Dysregulation of PDZRN3 expression or LNX3-mediated ubiquitination has been reported in disease-relevant contexts including aberrant growth control and fibrotic or inflammatory remodeling, supporting its use in mechanistic studies of signaling and proteostasis.
LNX3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PDZRN3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PDZRN3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PDZRN3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LNX3 protein expression.
This CRISPR knockout system enables efficient generation of PDZRN3-deficient cell models for investigation of LNX3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PDZRN3 exon(s) critical for LNX3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PDZRN3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LNX3 CRISPR/Cas9 KO Plasmid (h) and LNX3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PDZRN3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LNX3 HDR Plasmid (h) and LNX3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PDZRN3 homology arms to support homology-directed repair at defined PDZRN3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.